Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 5, September-October, p. 545–551

Publication type: original article

Language: English

In vitro Activity of Tigecycline Against Clinical Isolates of Gram−Positive and Gram−Negative Bacteria Displaying Different Resistance Phenotypes

Aktywność in vitro tigecykliny wobec izolatów klinicznych bakterii Gram−dodatnich i Gram−ujemnych o różnych fenotypach oporności

Roman Franiczek1,, Izabela Dolna1,, Ewa Dworniczek1,, Barbara Krzyżanowska1,, Alicja Seniuk1,, Elżbieta Piątkowska1,

1 Department of Microbiology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Objectives. The aim of the study was to evaluate the in vitro activity of tigecycline against clinically relevant isolates of Gram−positive and Gram−negative bacteria resistant to different antimicrobial drugs.
Material and Methods. A total of 495 clinical isolates, including methicillin−resistant Staphylococcus aureus (MRSA) (n = 19), methicillin−resistant coagulase−negative Staphylococcus spp. (MRCNS) (n = 56), methicillinsusceptible Staphylococcus aureus resistant to tetracycline (MSSA TR) (n = 113), high−level aminoglycoside−resistant (HLAR) Enterococcus spp. (n = 181), and extended−spectrum β−lactamase (ESBL)−producing bacilli (n = 126), were used in this study. The clinical isolates were obtained from patients hospitalized at the Medical University Hospital in Wrocław, Poland, during a three−year period (2005–2007). The minimal inhibitory concentrations (MICs) of tigecycline for the strains were determined by the agar dilution technique on Mueller−Hinton agar.
Results. Tigecycline exhibited excellent activity against all Gram−positive cocci tested, with MIC90 values ranging from 0.03 to 0.06 mg/L. In addition, this antimicrobial was also very potent against all ESBL−producing strains tested with an MIC90 of 0.25 mg/L. The activity of tigecycline against ESBL−producers was comparable to that of imipenem.
Conclusion. Tigecycline could be considered an alternative antibacterial agent for the treatment of serious infections caused by drug−resistant bacterial strains.

Streszczenie

Cel pracy. Określenie aktywności in vitro tigecykliny wobec ważnych z klinicznego punktu widzenia szczepów bakterii Gram−dodatnich i Gram−ujemnych opornych na różne leki przeciwbakteryjne.
Materiał i metody. Wbadaniach zastosowano 495 izolatów klinicznych obejmujących: metycylinooporne szczepy Staphylococcus aureus (MRSA) (n = 19), koagulazoujemne szczepy Staphylococcus spp. oporne na metycylinę (MRCNS) (n = 56), metycylinowrażliwe szczepy Staphylococcus aureus oporne na tetracyklinę (MSSA TR) (n = 113), szczepy Enterococcus spp. oporne na wysokie stężenia aminoglikozydów (HLAR) (n = 181) oraz pałeczki wytwarzające β−laktamazy o rozszerzonym spektrum substratowym (ESBL) (n = 126). Szczepy kliniczne wyizolowano od pacjentów hospitalizowanych w Akademickim Szpitalu Klinicznym we Wrocławiu w ciągu 3 lat (2005–2007). Minimalne stężenia hamujące tigecykliny (MIC) dla badanych szczepów oznaczono metodą seryjnych rozcieńczeń w podłożu agarowym Mueller−Hintona.
Wyniki. Tigecyklina wykazywała doskonałą aktywność wobec wszystkich badanych ziarenkowców Gram−dodatnich, dla których wartości MIC90 zawierały się w przedziale 0,03–0,06 mg/l. Antybiotyk ten okazał się także bardzo skuteczny wobec wszystkich szczepów wytwarzających ESBL; wartość MIC90 dla tych izolatów wynosiła 0,25 mg/l. Aktywność tigecykliny wobec ESBL−dodatnich szczepów była porównywalna z aktywnością imipenemu.
Wnioski. Tigecyklina może być alternatywnym lekiem przeciwbakteryjnym w leczeniu poważnych zakażeń powodowanych przez lekooporne szczepy bakteryjne.

Key words

tigecycline, MRS, HLAR, ESBL

Słowa kluczowe

tigecyklina, MRS, HLAR, ESBL

References (32)

  1. Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65, 232–260.
  2. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9−t−butylglycylamido derivative of minocycline (GAR−936). Antimicrob Agents Chemother 1999, 43, 738–744.
  3. Townsend ML, Pound MW, Drew RH: Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006, 60, 1662–1672.
  4. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ: Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006, 4, 9–25.
  5. Bergeron J, Ammirati M, Danely D, James L, Norcia M, Retsema J, Strick CA, Su WG, Sutcliffe J, Wondrack L: Glycylcyclines bind to the high−affinity tetracycline ribosomal binding site and evade Tet(M)− and Tet(O)−mediated ribosomal protection. Antimicrob Agents Chemother 1996, 40, 2226–2228.
  6. Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of GAR−936 tested against antibiotic−resistant Gram−positive bloodstream infection isolates and strains producing expended−spectrum β−lactamases. Diagn Microbiol Infect Dis 2001, 40, 173–177.
  7. Morosini MI, Garcia−Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Canton R: Antibiotic coresistance in extended−spectrum−β−lactamase−producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006, 50, 2695–2699.
  8. Sorlozano A, Gutierrez J, Salmeron A, Luna JD, Martinez−Checa F, Roman J, Piedrola G: Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended−spectrum β−lactamase−producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006, 28, 532–536.
  9. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ: In vitro and in vivo antibacterial activities of tigecycline (GAR−936), daptomycin, and comparative antimicrobial agents against glycopeptideintermediate Staphylococcus aureus and other resistant Gram−positive pathogens. Antimicrob Agents Chemother 46, 2002, 2595–2601.
  10. Cercenado E, Cerconado S, Gómez JA, Bouza E: In vitro activity of tigecycline (GAR−936), a novel glycylcycline, against vancomycin−resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003, 52, 138–139.
  11. Betriu C, Rodriguez−Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ: Spanish Group of Tigecycline: In vitro activities of tigecycline (GAR−936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002, 46, 892–895.
  12. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC: Activities of the glycylcycline tigecycline (GAR−936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003, 47, 400–404.
  13. Jarlier V, Nicolas MH, Fournier G, Philippon A: Extended broad−spectrum β−lactamases conferring transferable resistance to newer β−lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10, 867–878.
  14. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. Wayne PA, USA 2006, 16th Informational Supplement, M100–S15.
  15. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Wayne PA, USA 2006, 7th Approved Standard Guideline, M7–A7.
  16. Wyeth Pharmaceutics: Tygacil (tigecycline) for injection [package insert]: Wyeth Pharmaceuticals Inc PA USA, 2005.
  17. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler ML, Beach ML: Survey of blood stream infections attributable to Gram−positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999, 33, 283–297.
  18. Tenover FC: Implications of vancomycin−resistant Staphylococcus aureus. J Hos Infect 1999, 43, S3–S7.
  19. Johnson AP, Henwood C, Mushtaq S, James D, Warner M, Livermore DM, ICU Study Group: Susceptibility of Gram−positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J Hosp Infect 2003, 54, 179–187.
  20. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ: Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006, 44, 3368–3370.
  21. Kola A, Kirschner P, Gohrbandt B, Chaberny IF, Mattner F, Struber M, Gastmeier P, Suerbaum S: An infection with linezolid−resistant S. aureus in a patient with left ventricular assist system. Scand J Infect Dis 2007, 39, 463–465.
  22. Willems RJ, Bonten MJ: Glycopeptide−resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007, 20, 384–390.
  23. BoucherHW, Wennersten CB, Eliopoulos GM: In vitro activities of the glycylcyclines GAR−936 against Gram−positive bacteria. Antimicrob Agents Chemother 2000, 44, 2225–2229.
  24. Livermore DM: β−lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8, 557–584.
  25. Paterson DL, Bonomo RA: Extended−spectrum β−lactamases: a clinical update. Clin Microb Rev 2005, 18, 657–686.
  26. Schwaber MJ, Navon−Venezia S, Schwartz D, Carmeli Y: High levels of antimicrobial coresistance among extended−spectrum−β−lactamase−producing Enterobacteriaceae. Antimicrob Agents Chemother 2005, 49, 2137–2139.
  27. Jacoby GA, Sutton L: Properties of plasmids responsible for production of extended−spectrum β−lactamases. Antimicrob Agents Chemother 1991, 35, 164–169.
  28. Livermore DM, Yuan M: Antibiotic resistance and production of extended−spectrum β−lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996, 38, 409–424.
  29. Paterson DL: Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended−spectrum β−lactamases (ESBLs). Clin Microb Infect 2000, 6, 460–463.
  30. Bratu S, Tolaney P, Karamundi U, Quale J, Mooty M, Nichani S, Landman D: Carbapenemase−producing Klebsiella pneumoniae in Brooklyn, N.Y.: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56, 2005, 128–132.
  31. Woodford N, Dallow JW, Hill RL, Palepou MF, Pike R, Ward ME, Warner M, Livermore DM: Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007, 29, 456–459.
  32. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, Kannavaki S, Giamarellou H: In vitro activity of tigecycline against multiple−drug−resistant, including pan−resistant, Gram−negative and Gram−positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006, 50, 3166–3169.
© Wroclaw Medical University